Patient Characteristics and Exercise Performance
| Characteristic | Ex 8 group (n = 48) | Ex 48 group (n = 45) | No Ex group (n = 34) |
| Sex (n) | |||
| Male | 26 | 27 | 16 |
| Female | 22 | 18 | 18 |
| Age (y) | |||
| Mean | 62.5 | 54.6 | 62 |
| Range | 45–80 | 15–83 | 30–86 |
| Time interval (h:min) from MPI to 18F-FDG injection | |||
| Mean | 4:05 | 38:38 | — |
| Range | 00:38–08:29 | 24:21–47:11 | |
| 18F-FDG activity | |||
| Mean | 560.55 MBq; 15.15 mCi | 539.46 MBq; 14.58 mCi | 554.26 MBq; 14.98 mCi |
| Range | 499.5–610.5 MBq; 13.5–16.5 mCi | 410.7–610.5 MBq; 11.1–16.5 mCi | 418.1–610.5 MBq; 11.3–16.5 mCi |
| 18F-FDG uptake time (min) | |||
| Mean | 69 | 67 | 65 |
| Range | 54–130 | 52–104 | 51–86 |
| Blood glucose (mg/dL) | |||
| Mean | 88 | 100 | 94 |
| Range | 50–173 | 70–173 | 49–121 |
| PET indication (n) | |||
| Staging | 34 | 22 | 6 |
| Restaging or response assessment | 14 | 23 | 28 |
| Chemotherapy within 3 wk before PET and MPI | 4 | 3 | 7 |
| Exercise duration (min:s) | — | ||
| Mean ± SD | 7:30 ± 2:08 | 7:30 ± 2:23 | |
| 95% confidence interval | 6:53–8:08 | 6:47–8:14 | |
| METs | — | ||
| Mean ± SD | 8.4 ± 2.3 | 8.9 ± 2.6 | |
| 95% confidence interval | 7.72–9.04 | 8.14–9.66 | |
| Achieved 85% of maximum predicted heart rate (n) | 44/48 (91.6%) | 40/45 (88.9%) | — |
| VO2max (ml O2 × kg−1 × min−1) | — | ||
| Mean ± SD | 32.4 ± 5.7 | 30.7 ± 6.7 | |
| 95% confidence interval | 30.79–34.01 | 28.74–32.66 |
* Based on http://www.concept2.com/us/interactive/calculators/vo2max.asp, accessed on Nov. 17, 2011; 85% calculation was done using upper thresholds of average VO2max per age group as denominator.
Prior chemotherapy included platinum-based regimens (CHOP, etoposide, capecitabine).
VO2max = maximal oxygen uptake.